2029, Biosimilars and Vaccines

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2029

Biosimilars

Vaccines

Biopharma sees strong Q2 2023 market cap growth

European Pharmaceutical Review

AUGUST 21, 2023

Part of this growth was driven by Arexvy, which in May 2023, became the world’s first approved RSV vaccine for older adults. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. Merck & Co Merck & Co reached third in ranking, due to 8.4

Biosimilars

Biosimilars Diabetes Vaccines

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

covered insulin product or vaccine). Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. state pharmaceutical assistance programs). had Part D expenditures on or before August 16, 2022).

Labelling

Labelling Drug Pricing Compounding Payment Processing

Pharmacist Digest

Biopharma sees strong Q2 2023 market cap growth

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

Stay Connected